USOR 22229 - Ph3 Dato-Dxd Pembro PD-L1 < 50% NSCLC (TL07)

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles